{"id":"efb006b8-a755-5fe7-adcf-d6a6a39da6c0","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-hepg2-lipids","predicate":"decreases_in_recorded_comparison","statement":"Apigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"12459866-c7cf-5609-b8ef-41caa9c73f79","mechanism_event_label":"Apigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"b928e74c-70d4-5fb3-92fd-9e12dabad809","slug":"human-apigenin-hepg2-triglycerides","display_name":"HepG2 triglycerides in the apigenin lipid-loading experiment","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"12459866-c7cf-5609-b8ef-41caa9c73f79","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-hepg2-lipids-event","event_type":"experimental_observation","label":"Apigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.","description":"### api-hepg2-lipids\n\nApigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.\nDoes not identify fatty-acid oxidation flux as the sole cause.\nModel and exposure: 0.5 mM oleate/palmitate, 2:1; 25 micromolar apigenin.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin during lipid loading","sequence_order":0,"notes":""},{"entity":{"id":"b928e74c-70d4-5fb3-92fd-9e12dabad809","slug":"human-apigenin-hepg2-triglycerides","display_name":"HepG2 triglycerides in the apigenin lipid-loading experiment","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"b8e1bfa9-c412-5f35-97af-cfc722123d27","slug":"sirt1","display_name":"SIRT1","entity_type_key":"protein"},"role":"inhibitor-sensitive pathway","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"b6d0917f-86b4-5781-987a-58de0219dede","slug":"ex527","display_name":"EX-527 / selisistat experimental SIRT1 inhibitor","entity_type_key":"drug"},"role":"blocking comparator","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin during lipid loading\", \"comparator\": \"Same lipid loading without apigenin\", \"endpoint\": \"Apigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"0.5 mM oleate/palmitate, 2:1; 25 micromolar apigenin.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-hepg2-lipids; Does not identify fatty-acid oxidation flux as the sole cause.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8ef5ffd1-4987-52bc-a89e-67c280924586","evidence_kind":"source_excerpt","locator":"Lines 208-214","start_line":208,"end_line":214,"excerpt":"### api-hepg2-lipids\n\nApigenin reduced triglyceride accumulation in lipid-loaded HepG2 cells; EX-527 suppressed the response.\nDoes not identify fatty-acid oxidation flux as the sole cause.\nModel and exposure: 0.5 mM oleate/palmitate, 2:1; 25 micromolar apigenin.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23172919/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3609577/ | https://doi.org/10.2337/db12-1139 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"0.5 mM oleate/palmitate, 2:1; 25 micromolar apigenin.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}